Five Prime Therapeutics Inc. (FPRX) Soars 6.63%

Five Prime Therapeutics Inc. (FPRX) Soars 6.63%

Five Prime Therapeutics Inc. (FPRX) had a good day on the market for Friday November 22 as shares jumped 6.63% to close at $3.54. About 1.53 million shares traded hands on 2,832 trades for the day, compared with an average daily volume of n/a shares out of a total float of 36.78 million. After opening the trading day at $3.31, shares of Five Prime Therapeutics Inc. stayed within a range of $3.65 to $3.31.

With today’s gains, Five Prime Therapeutics Inc. now has a market cap of $130.21 million. Shares of Five Prime Therapeutics Inc. have been trading within a range of $13.97 and $3.18 over the last year, and it had a 50-day SMA of $n/a and a 200-day SMA of $n/a.

Five Prime Therapeutics Inc is a biotechnology company focused on discovering and developing protein therapeutics for diseases. The company’s product candidates address patient populations for which therapies are still needed. Its is focused on advancing its internal pipeline and retaining rights for products in targeted specialty markets. It also seeks to establish additional collaborations to supplement its internal development capabilities. These collaborations generate additional funding in order to further validate the company’s technology. It has the following product in pipeline: Cabiralizumab, FPA150, Bemarituzumab and Immuno-Oncology.

Five Prime Therapeutics Inc. is based out of South San Francisco, CA and has some 210 employees. Its CEO is William R. Ringo.

error: Content is protected !!